Mariner LLC Invests $418,000 in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Mariner LLC acquired a new position in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,303 shares of the company's stock, valued at approximately $418,000.

A number of other institutional investors also recently modified their holdings of the company. Barclays PLC boosted its position in shares of Soleno Therapeutics by 141.1% in the 4th quarter. Barclays PLC now owns 126,675 shares of the company's stock worth $5,694,000 after purchasing an additional 74,130 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in Soleno Therapeutics by 24.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,677 shares of the company's stock worth $120,000 after buying an additional 522 shares during the last quarter. F M Investments LLC acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth about $2,148,000. CenterBook Partners LP bought a new stake in shares of Soleno Therapeutics in the 4th quarter valued at about $1,355,000. Finally, Martingale Asset Management L P raised its position in shares of Soleno Therapeutics by 14.6% in the 4th quarter. Martingale Asset Management L P now owns 25,178 shares of the company's stock valued at $1,132,000 after acquiring an additional 3,203 shares during the period. Institutional investors own 97.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SLNO. UBS Group set a $105.00 price objective on shares of Soleno Therapeutics in a report on Thursday, March 27th. HC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of Soleno Therapeutics in a report on Tuesday, April 15th. Laidlaw raised their price objective on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Robert W. Baird boosted their target price on Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald increased their price target on Soleno Therapeutics from $67.00 to $123.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $104.67.

Soleno Therapeutics Trading Up 1.9 %

Shares of SLNO stock traded up $1.40 on Wednesday, hitting $75.11. 519,430 shares of the stock were exchanged, compared to its average volume of 726,617. The firm has a market capitalization of $3.75 billion, a P/E ratio of -22.62 and a beta of -2.67. Soleno Therapeutics, Inc. has a fifty-two week low of $36.93 and a fifty-two week high of $78.00. The business has a 50-day moving average of $61.48 and a 200 day moving average of $53.89.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41). As a group, research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Insider Activity at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,782 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $70.11, for a total transaction of $265,156.02. Following the transaction, the insider now directly owns 27,036 shares in the company, valued at $1,895,493.96. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Michael F. Huang sold 14,583 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $69.51, for a total value of $1,013,664.33. Following the completion of the sale, the vice president now owns 36,817 shares in the company, valued at $2,559,149.67. This represents a 28.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 942,672 shares of company stock valued at $64,058,781. 12.30% of the stock is owned by insiders.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.